Celltrion Files First Rituximab Biosimilar In Europe
This article was originally published in PharmAsia News
Executive Summary
Following the launch of its biosimilar version of Remicade, South Korea’s Celltrion has applied for European approval of its second biosimilar candidate, rituximab, marking the first filing in Europe for a biosimilar of the CD20-targeted oncology antibody.